Lambert-Eaton myasthenic syndrome

Lambert-Eaton myasthenic syndrome
Global view of a neuromuscular junction: 1. Axon 2. Motor end-plate 3. Muscle fiber 4. Myofibril
ICD-10	G73.1
ICD-9	358.1
DiseasesDB	4030
MedlinePlus	000710
MeSH	D015624

WikiDoc Resources for Lambert-Eaton myasthenic syndrome
Articles
Most recent articles on Lambert-Eaton myasthenic syndrome Most cited articles on Lambert-Eaton myasthenic syndrome Review articles on Lambert-Eaton myasthenic syndrome Articles on Lambert-Eaton myasthenic syndrome in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Lambert-Eaton myasthenic syndrome Images of Lambert-Eaton myasthenic syndrome Photos of Lambert-Eaton myasthenic syndrome Podcasts & MP3s on Lambert-Eaton myasthenic syndrome Videos on Lambert-Eaton myasthenic syndrome
Evidence Based Medicine
Cochrane Collaboration on Lambert-Eaton myasthenic syndrome Bandolier on Lambert-Eaton myasthenic syndrome TRIP on Lambert-Eaton myasthenic syndrome
Clinical Trials
Ongoing Trials on Lambert-Eaton myasthenic syndrome at Clinical Trials.gov Trial results on Lambert-Eaton myasthenic syndrome Clinical Trials on Lambert-Eaton myasthenic syndrome at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Lambert-Eaton myasthenic syndrome NICE Guidance on Lambert-Eaton myasthenic syndrome NHS PRODIGY Guidance FDA on Lambert-Eaton myasthenic syndrome CDC on Lambert-Eaton myasthenic syndrome
Books
Books on Lambert-Eaton myasthenic syndrome
News
Lambert-Eaton myasthenic syndrome in the news Be alerted to news on Lambert-Eaton myasthenic syndrome News trends on Lambert-Eaton myasthenic syndrome
Commentary
Blogs on Lambert-Eaton myasthenic syndrome
Definitions
Definitions of Lambert-Eaton myasthenic syndrome
Patient Resources / Community
Patient resources on Lambert-Eaton myasthenic syndrome Discussion groups on Lambert-Eaton myasthenic syndrome Patient Handouts on Lambert-Eaton myasthenic syndrome Directions to Hospitals Treating Lambert-Eaton myasthenic syndrome Risk calculators and risk factors for Lambert-Eaton myasthenic syndrome
Healthcare Provider Resources
Symptoms of Lambert-Eaton myasthenic syndrome Causes & Risk Factors for Lambert-Eaton myasthenic syndrome Diagnostic studies for Lambert-Eaton myasthenic syndrome Treatment of Lambert-Eaton myasthenic syndrome
Continuing Medical Education (CME)
CME Programs on Lambert-Eaton myasthenic syndrome
International
Lambert-Eaton myasthenic syndrome en Espanol Lambert-Eaton myasthenic syndrome en Francais
Business
Lambert-Eaton myasthenic syndrome in the Marketplace Patents on Lambert-Eaton myasthenic syndrome
Experimental / Informatics
List of terms related to Lambert-Eaton myasthenic syndrome

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]

Synonyms and keywords: Eaton-Lambert syndrome; Lambert-Eaton syndrome; LEMS

Overview

Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune disorder which affects the nerve-muscle (neuromuscular) junction.

The disease is usually observed in middle aged and older people but children and young people can be affected, as well. Due to the infrequency of the condition, the exact incidence is unknown.

History

Anderson was the first person to mention a case with possible clinical findings of LEMS in 1953, but Lambert, Eaton and Rooke were the first physicians to substantially describe the clinical and electrophysiological findings of the disease in 1966. Auto-immune self antibodies to the pre-synaptic voltage gated calcium channels leads to neuromuscular block.

Pathophysiology

The disease is of autoimmune origin, that is, it is caused by antibodies that are directed against the antigens of the neuromuscular junction. In 1989, the previously anticipated antibodies were demonstrated to be directed against presynaptic calcium channels, which are located in neuromuscular junction (see synapse) and are responsible for the efficient release of acetylcholine. The antibodies prevent normal function of calcium channels and thus prevent the release of acetylcholine that is essential for normal nerve-muscle interactions, which maintain the normal muscle strength (see synapse, nerve, neuron, muscle).

There are also some patients that do not carry these antibodies in their serum samples and the exact cause of disease in these cases still remains to be determined. In cases with both LEMS and lung cancer (usually small cell type), the antibodies are suggested to be aimed at cancer cells and to bind and affect the antigens in neuromuscular junction accidentally. LEMS can be observed in other types of cancer including the transitional cell carcinoma of the bladder.

Approximately 50% of LEMS cases have an identifiable malignancy.

Causes

LEMS is usually a solitary diagnosis but lung cancer (small-cell histology) may accompany the disease in some cases. It may also be associated with cancers such as lymphoma, non-Hodgkin's lymphoma, T-cell leukemia, non-small cell lung cancer, prostate cancer, and thymoma.

Diferentiating from other Diseases

Both the etiology and the clinical findings of Lambert-Eaton myasthenic syndrome may resemble myasthenia gravis, but there are many substantial differences between clinical presentations and pathogenetic features of two disorders. In patients with affected ocular and respiratory muscles, the involvement is not as severe as myasthenia gravis.

Diagnosis

Symptoms

• The major clinical finding is progressive weakness that does not usually involve the respiratory muscles and the muscles of face. In patients with affected ocular and respiratory muscles, the involvement is not severe. The proximal parts of the legs and arms are predominantly affected.
• Many patients have autonomic symptoms like dry mouth or impotence. Reflexes are usually reduced or absent.

Laboratory Findings

• Antibodies to calcium channels
• Incremental response in repetitive nerve stimulation - incremental response is an increased response of muscle fibers to very high frequencies of electrical stimulation. Observed increase in the response of muscle fibers proves that there is a difficulty with the release of acetylcholine and this difficulty can be overwhelmed by intensive stimulation.

Chest X-ray

• Chest x-ray for a possible lung malignancy

Treatment

Corticosteroids, azathioprine and 3,4-diaminopyridine are used in treatment of LEMS with limited success. In some cases with a progressive and intractable course, plasma exchange or intravenous immunoglobulin can be tried.

3,4 diaminopyridine works by blocking K+ channel efflux in nerve terminal so that action potential duration is increased. Ca2+ channels can then be open for longer time and allow greater acetylcholine release to stimulate muscle at end plate.

References

Template:Muscular Dystrophy